administered with DHA ethylester (97% purity) by forced oral administration at 0.7 ml/day for 4 weeks (6 days a week), and treated for autopsy. Each of the number of lesion (aberrant crypt mass) in a rat, the number of aberrant crypt in the caecum, the proximal colon, the distal colon, and the rectum in a rat, and the mean number of aberrant crypt in a lesion was reduced, compared to the control (rats administered with purified water).
Dwg.0/0
Title Terms: AGENT; INHIBIT; ABNORMAL; TISSUE; PROLIFERATION; CONTAIN; DOCOSA; HEXA; ENOIC; ACID; TREAT; NODE; HYPERPLASIA; LIVER
Derwent Class: B05
International Patent Class (Main): A61K-031/20
File Segment: CPI
Manual Codes (CPI/A-N): B03-F; B05-B01P; B07-D04C; B10-A22; B10-B02B; B10-C04E; B14-H01B
Chemical Fragment Codes (M2):
01 H7 H723 J0 J011 J171 J271 M210 M212 M226 M231 M262 M272 M281 M320 M416 M781 M903 M904 P631 P721 P723 R04471-U R15960-U
Specific Compound Numbers: R04471-U; R15960-U
?t 007951351/9

007951351/9
DIALOG(R)File 351:DERWENT WPI

007951351
WPI Accession No: 89-216463
XRAM Accession No: C89-096302
Anticancer agent with reduced side effects - contains docosahexaenoic acid or ester
Patent Assignee: NIPPON OILS & FATS CO LTD (NIOF); YAIZU SUISAN KAGAKU KOGY (YAIZ-N)
Number of Countries: 001 Number of Patents: 001
Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Main IPC	Week
JP 1153629	A	19890615	JP 87312236	A	19871211		198930 B

Priority Applications (No Kind Date): JP 87312236 A 19871211
Patent Details:

Patent	Kind	Lan	Pg	Filing Notes	Application	Patent
JP 1153629	A		6			

B13
B23

Abstract (Basic): JP 1153629 A
Anticancer agent contains as the active component docosahexaenoic acid (I) and/or ester.
USE/ADVANTAGE - The anticancer agent has reduced side effects.
In an example, fish oil contg. not less than 20% of (I), such as bonito oil and tuna oil, is used as the raw material and ethyl esterified NaOH as the catalyst. Urea is added to the ester and the mixture is purified by mol. distn. to give an ester contg. 75% of (I). 120 rats are bred with a standard feed (CE-2 (RTM) made by Nippon Kurea) and 2mg of N-methyl-N-nitroso urea is dosed three times a week for 5 weeks in the

rectum. 0.2 ml of ethyl docosahexaenate (II) is dosed three a week for further 25 weeks in the stomach. The tumour formation rate is 65%. A control using physiological saline soln. shows tumour formation rate of 79%. The total number of tumours is 40 compared to 64 for the control.
0/0
Title Terms: ANTICANCER; AGENT; REDUCE; SIDE; EFFECT; CONTAIN; DOCOSA; HEXA ; ENOIC; ACID; ESTER
Derwent Class: B05
International Patent Class (Additional): A61K-031/20; C07C-057/12
File Segment: CPI
Manual Codes (CPI/A-N): B10-C04E; B10-G02; B12-G07
Chemical Fragment Codes (M2):
01 H7 H723 J0 J011 J171 J271 M210 M211 M212 M213 M214 M215 M216 M220 M221 M222 M225 M231 M232 M233 M262 M272 M281 M320 M416 M781 M903 M904 P633 8930-18001-U
Generic Compound Numbers: 8930-18001-U
?t 003925789/9

003925789/9
DIALOG(R)File 351:DERWENT WPI

003925789
WPI Accession No: 84-071333
XRAM Accession No: C84-030596
Anti-neoplastic complex prepn. from active agent and unsatd. fatty aci - to give less toxic, more specific prod.
Patent Assignee: HIRAI H (HIRA-I)
Number of Countries: 001 Number of Patents: 002
Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Main IPC	Week
JP 59025327	A	19840209	JP 82133958	A	19820731		198412 B
JP 92049524	B	19920811	JP 82133958	A	19820731	A61K-031/71	199236

Priority Applications (No Kind Date): JP 82133958 A 19820731
Patent Details:

Patent	Kind	Lan	Pg	Filing Notes	Application	Patent
JP 59025327	A		4			
JP 92049524	B		5	Based on		JP 59025327

B6

Abstract (Basic): JP 59025327 A
Prepn. of an antineoplastic complex (I) is by reacting antineoplastics (II) with 10-30C unsatd. fatty acids. (II) are e.g. aminoglycoside antibiotics including daunorubicin, doxorubicin and adriamycin. Arachidonic acid and docosahexaenoic acid are the most suitable fatty acids. (I) is much less toxic, and is more effective against target cancer cells. In an example, 24.1 mg. of water-soluble carbodiimide were added to 10.3 mg. of arachidonic acid, the mixt. was dissolved in 3 ml. of DMF and 10.0 mg. of daunorubicin in 2 ml. of distilled water were added dropwise with stirring. The mixture was stirred for about 6 hrs., then adjusted to alkaline pH with 4N NaOH. The complex was extracted with 3 x 40 ml. of chloroform and the